Friday 16 October 2026
Export ADCT’s income statement to Excel — free account
ADC Therapeutics SA
ADCT Healthcare Biotechnology
ADC Therapeutics SA’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.17%, EPS grew 78.0%, free cash flow grew 51.0% and total debt rose 1.87%, each against the same quarter a year earlier.
1.41
0.08
−5.37%
Follow ADCT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.08 | 7.30 | 5.51 | 7.26 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(14.05) | (19.46) | (14.41) | (18.42) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.80 | 5.84 | 3.72 | 5.86 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.62) | (4.04) | (2.14) | (3.34) | |
EV/FCF |
(0.62) | (4.06) | (2.15) | (3.33) | |
Quick Ratio |
2.86 | 3.87 | 4.14 | 4.15 | |
Current Ratio |
3.03 | 4.09 | 4.37 | 4.63 | |
Net Debt/EBITDA |
4.03 | 4.59 | 8.19 | 3.86 | |
Debt/Assets |
41.74% | 39.68% | 35.73% | 39.76% | |
Debt/Equity |
(0.51) | (0.53) | (0.62) | (0.48) | |
Asset Turnover |
0.26 | 0.28 | 0.25 | 0.24 | |
Operating CF/Net income |
0.71 | 0.90 | 4.86 | 0.72 | |
Capex/Depreciation |
0.00 | (0.28) | 5.83 | 0.00 | |
Interest Coverage |
(1.88) | (2.04) | (1.38) | (2.31) | |
Research and Development Expense of Revenue |
90.22% | 95.33% | 78.86% | 163.16% | |
Selling, General and Administrative Expense of Revenue |
115.72% | 108.41% | 92.99% | 115.75% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
23.64% | 11.71% | 2.92% | 12.18% | |
Graham Net Nets |
(1.48) | (0.40) | (0.45) | (0.44) | |
Graham Number |
4.68 | 5.76 | 6.28 | 7.55 | |
Earnings Yield |
(61.68%) | (28.00%) | (33.99%) | (36.25%) | |
Free Cash Flow Yield |
(61.32%) | (19.72%) | (31.40%) | (24.25%) | |
Revenue per Share |
0.12 | 0.14 | 0.18 | 0.12 | |
Operating CF per Share |
(0.08) | (0.19) | (0.24) | (0.22) | |
Capex per Share |
0.00 | 0.00 | 0.01 | 0.00 | |
Free Cash Flow per Share |
(0.08) | (0.19) | (0.24) | (0.22) | |
Cash per Share |
1.41 | 1.50 | 2.06 | 1.72 | |
Shareholders Equity per Share |
(1.47) | (1.40) | (1.46) | (1.75) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.47) | (1.40) | (1.46) | (1.75) | |
Free Cash Flow |
(11.81) | (29.74) | (30.46) | (29.63) | |
Working Capital |
175.38 | 209.14 | 236.17 | 225.11 | |
Capital Expenditures |
0.00 | (0.03) | 0.66 | 0.00 | |
Net Current Asset Value |
(245.88) | (231.10) | (202.65) | (240.79) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | (0.03) | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
27.11 | 31.40 | 24.72 | 23.47 | |
Average Payables |
11.19 | 10.44 | 13.60 | 11.25 | |
Average Inventory |
11.35 | 11.11 | 3.22 | 17.06 | |
Average Assets |
300.47 | 282.02 | 322.57 | 319.42 | |
Average Common Equity |
(213.69) | (227.30) | (194.24) | (205.06) |
Columns are period end dates